The cholesterol-lowering drug has been classed as a breakthrough therapy for homozygous familial hypercholesterolaemia (HoFH) by the FDA, which is due to deliver a decision on the marketing ...
Because MHC class II expression is central to immune regulation in T-cell-mediated autoimmune disease, this effect of statins might contribute to the benefit conferred by drugs of this class in ...
The Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland, saying the evidence backing the drug isn’t strong enough.
Background: Statins are generally well tolerated, but some patients discontinue therapy secondary to adverse effects. Dosing a statin (rosuvastatin) every other day (EOD) may provide significant ...
Aug. 14, 2024 — More than a quarter of Australians over the age of 50 take cholesterol-lowering drugs to prevent heart disease and strokes, but our bodies also need cholesterol to survive.